SOLIGENIX, INC. Contractual Obligation, to be Paid, Year Five
SOLIGENIX, INC. (SNGX) had Contractual Obligation, to be Paid, Year Five of $46.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity › Contractual Obligation, to be Paid, Year Four and Five
us-gaap:ContractualObligationDueInFifthYear · last filed 2026-03-31
- 2025-12-31: Contractual Obligation, to be Paid, Year Five $46.00K.
- 2024-12-31: Contractual Obligation, to be Paid, Year Five $46.00K.
- 2023-12-31: Contractual Obligation, to be Paid, Year Five $46.00K.
- 2022-12-31: Contractual Obligation, to be Paid, Year Five $46.00K.
| Period end | Contractual Obligation, to be Paid, Year Five |
|---|---|
| 2025-12-31 | $46.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $46.00K 10-K · filed 2025-03-21 |
| 2023-12-31 | $46.00K 10-K · filed 2024-03-15 |
| 2022-12-31 | $46.00K 10-K · filed 2023-03-31 |
| 2021-12-31 | $100.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |